¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ : 2021-04-02

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ : 2021-04-02
±³À°ÀÏÀÚ : 2021-04-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ(18.7 ¸íĪº¯°æ ´ëÇÑÈ­Çпä¹ýÇÐȸ)
´ã´çÀÚ : ¹Ú½ÂÀ±
¿¬¶ôó : 02-557-1755  
À̸ÞÀÏ : ksc@ksac.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í Á¤È¸¿ø Àü°øÀÇ 5¸¸¿ø ÀüÀÓÀÇ 8¸¸¿ø Àü¹®ÀÇ ¹× ÀÏ¹Ý 10¸¸¿øºñȸ¿ø Àü°øÀÇ 7¸¸¿ø ÀüÀÓÀÇ 10¸¸¿ø Àü¹®ÀÇ ¹× ÀÏ¹Ý 12¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ08:00~08:50 CMV management strategy in allo-HSCT - After LETERMOVIR  À̵¿°Ç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ09:00~09:25 Treatment strategy: the Korean guideline  ¿°Áؼ·(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ09:25~09:50 Treatment strategy: the Korean experience  ±èÁø¿ë(ÀÎõÀÇ·á¿ø) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ09:50~10:15 Diagnostic strategy: diagnostic tests for COVID-19  È«±âÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ10:15~10:40 Diagnostic strategy: the role of rapid diagnostics  ±è³²Áß(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ10:50~11:25 COVID-19 vaccines  ÃÖ¿ø¼®(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ11:25~12:00 Future of COVID-19 in the post-vaccine era  Á¤ÀçÈÆ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ12:30~13:00 Special Lecture  ±è¹ÎÀÚ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ13:00~13:50 The strategy of rapid initiation with BIKTARVY  ±èÅÂÇü(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ15:20~15:45 Vancomycin vs. metronidazole for clostridium difficile infection  ±èÁöÀº(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ15:45~16:10 Beta-lactam/beta-lactamase inhibitors for ESBL-producing pathogens  ±Ç±âÅÂ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ16:10~16:35 Combination vs. monotherapy for severe MRSA infections  ¼Û°æÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ16:35~17:00 Combination vs. monotherapy for severe carbapenem-resistant GNR infections  °­Ã¶ÀÎ(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ : 2021-04-02""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) Á¦62Â÷ ´ëÇÑÀÌ°úÇÐȸ Çмú´ëȸ : 2021-04-03
´ÙÀ½±Û ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÆ÷Áö¾ö : 2021-04-02
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 76 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 39 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 45 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 34 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 25 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 23 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 30 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 24 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 16 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 28 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 31 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 32 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 39 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 26 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 31 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷